Dose Insider / Glossary / SURMOUNT-1

SURMOUNT-1The trial behind Zepbound and what it found

Updated November 20, 2026 · 3 min read · Jastreboff et al., N Engl J Med 2022; ZEPBOUND label

SURMOUNT-1 is the main trial behind the approval of Zepbound for weight management. It enrolled 2,539 adults with obesity, or with overweight and a weight-related complication, who did not have diabetes, and gave them tirzepatide 5 mg, 10 mg or 15 mg, or placebo, once a week for 72 weeks.

20.9%15 mg, weight lost by week 72
Weight lost by week 72SURMOUNT-1, % of starting weight15 mg20.9%10 mg19.5%5 mg15.0%Placebo3.1%Weight lost by week 72SURMOUNT-1, % of starting weight15 mg20.9%10 mg19.5%5 mg15.0%Placebo3.1%

57% on 15 mg lost 20% or more of their weight, against 3% on placebo.

On this page

Weight fell by 15.0%, 19.5% and 20.9% on the three doses, against 3.1% on placebo. It was published in the New England Journal of Medicine in 2022.1

How the trial was run

Participants had a body mass index of 30 or more, or 27 or more with at least one weight-related complication, and were assigned in equal shares to the three doses and placebo. The 72 weeks included a 20-week period of rising doses: every dose started at 2.5 mg and climbed by 2.5 mg every 4 weeks to its target.1,2 At the start, people weighed 104.8 kg on average, with a body mass index of 38.0, and 94.5% had a body mass index of 30 or more.1

The main analysis counted everyone as assigned, regardless of whether they stopped treatment, which makes the numbers closer to real use. The two main outcomes were the percentage change in weight and the share losing at least 5%.1

What it found

Jastreboff et al., 2022.1

The Zepbound label reports the same trial in the same terms. On 15 mg, 56.7% lost at least 20% of their weight, and the placebo group started at 104.8 kg.2 Our page on the Zepbound dosing schedule turns the same dose steps into dates.

Side effects

The most common side effects were in the stomach and gut, mostly mild to moderate and mainly during the dose climb. Adverse events led 4.3%, 7.1% and 6.2% on the three doses to stop, against 2.6% on placebo.1 On the Zepbound label, nausea was reported by 25%, 29% and 28% against 8% on placebo.2 Our Zepbound side effects timeline shows when they tend to start and fade.

Why it matters

In SURMOUNT-1, half or more of the people on the two higher doses lost a fifth of their weight, against 3% on placebo. That result set the benchmark for the trials that followed: semaglutide 2.4 mg had lowered weight by 14.9% over 68 weeks in STEP 1, though the trials differ and were not run against each other.3 The direct comparison came later, in SURMOUNT-5, where weight fell by 20.2% on tirzepatide against 13.7% on semaglutide.4

It also shows that the middle dose does most of the work. Going from 10 mg to 15 mg added 1.4 points of weight loss on average, while going from 5 mg to 10 mg added 4.5.1 That is one reason the Zepbound label lists 5, 10 and 15 mg as maintenance doses rather than pushing everyone to the top.2

Limits

The trial excluded people with diabetes, who were studied in SURMOUNT-2 and lost less weight. It lasted 72 weeks, so it does not show long-term results. It was funded by Eli Lilly, the maker of tirzepatide. The label approves Zepbound only together with a reduced-calorie diet and more physical activity, the setting in which its results apply.1,5

Sources

  1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216. NCT04184622. doi:10.1056/NEJMoa2206038
  2. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 2, 6.1 and 14. accessdata.fda.gov
  3. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989-1002. doi:10.1056/NEJMoa2032183
  4. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med 2025;393:26-36. nejm.org
  5. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet 2023;402:613-626. Funded by Eli Lilly and Company. doi:10.1016/S0140-6736(23)01200-X

Related analyses

Log your weight weekly and see how your curve compares with the trial's.

Open Dose Insider